Clinical Trial Update: Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cetuximab with biweekly capecitabine and oxaliplatin in KRAS wild-type metastatic colorectal cancer has completed; results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Cetuximab (cetuximab)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: NYU Langone Health | Conditions: Colorectal Cancer, Neoplasm Metastasis | Phase 2 | Status: COMPLETED | Results posted: 2020-04-03